Stentys names chief medical officer

Previously at ev3, Dr Spaargaren was vice president of international clinical affairs since 2002, where he was responsible for driving new product development from R&D to acceptance by the medical community and launch into international markets.

Prior to ev3, Dr Spaargaren served for seven years from 1995 to 2002 with Boston Scientific as medical director for Europe, and for three years from 1992 to 1995 as clinical manager for Europe with Medtronic (Cardiac Assist Venture).

Gonzague Issenmann, Stentys’s CEO and co-founder, said: “No doubt, he will play a critically important role in helping to establish that the Stentys bifurcation stent is as easy for cardiologists to use as conventional stents – but that our bifurcation stent is designed to provide superior treatment options by enabling full opening of the side branch.”